- Research article
- Open Access
- Open Peer Review
Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2
© Mohamedali et al; licensee BioMed Central Ltd. 2011
- Received: 19 April 2011
- Accepted: 17 August 2011
- Published: 17 August 2011
The fusion protein VEGF121/rGel composed of the growth factor VEGF121 and the plant toxin gelonin targets the tumor neovasculature and exerts impressive anti-vascular effects. We have previously shown that VEGF121/rGel is cytotoxic to endothelial cells overexpressing VEGFR-2 but not to endothelial cells overexpressing VEGFR-1. In this study, we examined the basis for the specific toxicity of this construct and assessed its intracellular effects in vitro and in vivo.
We investigated the binding, cytotoxicity and internalization profile of VEGF121/rGel on endothelial cells expressing VEGFR-1 or VEGFR-2, identified its effects on angiogenesis models in vitro and ex vivo, and explored its intracellular effects on a number of molecular pathways using microarray analysis.
Incubation of PAE/VEGFR-2 and PAE/VEGFR-1 cells with 125I-VEGF121/rGel demonstrated binding specificity that was competed with unlabeled VEGF121/rGel but not with unlabeled gelonin. Assessment of the effect of VEGF121/rGel on blocking tube formation in vitro revealed a 100-fold difference in IC50 levels between PAE/VEGFR-2 (1 nM) and PAE/VEGFR-1 (100 nM) cells. VEGF121/rGel entered PAE/VEGFR-2 cells within one hour of treatment but was not detected in PAE/VEGFR-1 cells up to 24 hours after treatment. In vascularization studies using chicken chorioallantoic membranes, 1 nM VEGF121/rGel completely inhibited bFGF-stimulated neovascular growth. The cytotoxic effects of VEGF121/rGel were not apoptotic since treated cells were TUNEL-negative with no evidence of PARP cleavage or alteration in the protein levels of select apoptotic markers. Microarray analysis of VEGF121/rGel-treated HUVECs revealed the upregulation of a unique "fingerprint" profile of 22 genes that control cell adhesion, apoptosis, transcription regulation, chemotaxis, and inflammatory response.
Taken together, these data confirm the selectivity of VEGF121/rGel for VEGFR-2-overexpressing endothelial cells and represent the first analysis of genes governing intoxication of mammalian endothelial cells by a gelonin-based targeted therapeutic agent.
- Tube Formation
- Tumor Neovascularization
- IC50 Dose
- Fusion Toxin
Continuing investigations into the biology of tumor-stromal interactions have identified a number of pathways and events critical to the development and maintenance of tumors and their metastatic spread. Tumor neovascularization is a critical, robust process dependent on the interplay between numerous soluble cytokines, growth factors and their receptors. Targeted therapy focusing on the tumor neovascularization process appears to be a promising approach in this regard . The VEGF-A family of cytokines and their cognate receptors have been identified as key mediators of angiogenesis and endothelial cell proliferation, migration and survival [2–6], and play a central role in the organization of solid tumor vasculature [7, 8].
The smallest of the VEGF isoforms, VEGF121 binds to two receptors designated VEGFR-1 (Flt-1/FLT-1) and VEGFR-2 (Flk-1/KDR), both of which are over-expressed on the endothelium of tumor vasculature but virtually undetectable in the vascular endothelium of adjacent normal tissues. We have previously characterized a novel fusion construct of VEGF121 and the plant toxin Gelonin (rGel). Gelonin is a 28.5 kDa single-chain protein belonging to the family of Type 1 plant Ribosome-Inactivating Proteins (RIPs) that can hydrolyze the glycosidic bond of a highly conserved adenosine residue in the largest RNA in the 28S ribosome, resulting in irreversible inhibition of protein synthesis. In vivo, VEGF121/rGel targets and destroys tumor neovasculature in solid tumors [9, 10], reduces breast cancer metastatic spread and dramatically reduces neovascularization of pulmonary breast metastases , prevents tumor growth in bone in osteolytic and osteoblastic bone metastasis models [12, 13], and blocks retinal and choroidal neovascularization in studies of experimental ocular neovascular disease . The binding of VEGF121/rGel to both VEGFR-1 and VEGFR-2 has been demonstrated in vivo using non-invasive bioluminescence imaging (BLI), magnetic resonance imaging (MRI) and positron-emission tomography (PET) . Thus, VEGF121/rGel appears to be a promising candidate for targeting its cognate receptors in various disease states.
Interestingly, VEGF121/rGel demonstrates targeted toxicity in vitro to endothelial cells which over-express VEGFR-2 (IC50 = 0.5 - 1 nM) but not to cells which over-express VEGFR-1 (IC50 = 300 nM) compared to gelonin alone (IC50 = 300 nM) . This is surprising since VEGF121 binds to both receptors with affinity in the picomolar range . There are several possibilities that may account for this difference in toxicity: (a) the binding affinity of VEGF121/rGel to VEGFR-1 may be reduced, (b) binding affinity is not affected but the rate of internalization of VEGF121/rGel bound to VEGFR-1 is reduced compared to VEGFR-2 and (c) different access to the ribosomal machinery following cell entry due to being trapped in the endosomal compartment. In addition, while the molecular effects of VEGF121-treatment of endothelial cells have been studied , the effects of VEGF121/rGel on endothelial cells have yet to be elucidated. This information is critical in the context of in vivo targeting because of the potential role that stimulation by VEGF121 can have on cell survival and rGel-mediated toxicity. For example, VEGF121 may activate particular signal transduction pathways early in the process that can result in increased toxicity of the rGel component even prior to complete inhibition of protein synthesis. The biochemical process of drug action, and its off-target effects can best be studied under controlled conditions in vitro. In this report, we focus on understanding the mechanism of action of VEGF121/rGel on endothelial cells by determining its binding profile to VEGFR-1 and VEGFR-2, identifying its effects on angiogenesis models in vitro and ex vivo, and exploring its intracellular effects on a number of molecular pathways using microarray analysis.
Porcine aortic endothelial (PAE) cells transfected with the human VEGFR-2 (PAE/VEGFR-2) or the human VEGFR-1 (PAE/VEGFR-1) have been used as in vitro models of angiogenesis . The number of R-2 and R-1 receptor sites on these cells lines have been previously determined at 150,000 and 50,000 per cell, respectively . Human umbilical vein endothelial cells (HUVECs) were maintained in EBM medium (Cambrex, East Rutherford, NJ).
Purification of VEGF121/rGel
Construction and purification of VEGF121/rGel was essentially as described . VEGF121/rGel was concentrated and stored in sterile PBS at -20°C.
Western Blot Analysis
Whole cell extracts of HUVECs, PAE/VEGFR-2 and PAE/VEGFR-1 cells were prepared as described . Western blotting was performed using antibodies for actin (loading control), VEGFR-2, p-VEGFR-2 (p-KDR), E-selectin, and various apoptotis markers.
Cell Surface Binding of Radiolabeled VEGF121/rGel to PAE/VEGFR-2 and PAE/VEGFR-1 cells
VEGF121/rGel was radiolabeled with 1mCi of NaI125 using Chloramine T  for a specific activity of 602 Ci/mMol. Equivalent numbers of cells were grown overnight in 24-well plates and cell surface binding assays were performed as described previously . Briefly, non-specific binding sites were blocked for 30 minutes with PBS/0.2% gelatin followed by incubation for 4 hours at 4°C with 125I-VEGF121/rGel (10 nM) in PBS/0.2% gelatin solution. For competition experiments, cold VEGF121/rGel or gelonin (400 nM) were pre-mixed with 125I-VEGF121/rGel. Cells were washed four times with PBS/0.2% gelatin solution, detached and bound cpm was measured.
Cytoxicity and Internalization of VEGF121/rGel and rGel
Cytotoxicity of VEGF121/rGel and rGel against log phase PAE/VEGFR-2 cells was performed over 72 hours as described for PAE/KDR and PAE/FLT-1 cells . To assess if the activity of VEGF121/rGel was affected by the exposure time to endothelial cells, log-phase PAE/VEGFR-2 cells were treated with VEGF121/rGel and media containing the cytotoxic agent was removed at varying time-points and replaced with fresh media. For internalization, cells were treated with 4 μg/ml (48 nM) VEGF121/rGel at the timepoints indicated, then washed with Glycine buffer (500 mM NaCl, 0.1 M glycine, pH 2.5) to remove cell surface-bound VEGF121/rGel. Cells were incubated with a rabbit anti-gelonin polyclonal antibody (1:200) followed by a FITC-conjugated anti-rabbit secondary antibody (1:80). Nuclei were stained with propidium iodide (1 μg/ml) in PBS. The slides were mounted with DABCO reagent and visualized under fluorescence (Nikon Eclipse TS1000) and confocal (Zeiss LSM 510) microscopes.
Log phase PAE/VEGFR-2 and PAE/VEGFR-1 cells (2000 cells/well) were treated with 1 nM VEGF121/rGel for 72, 48 and 24-hours. The cells were then processed and analyzed for TUNEL as described by the manufacturer of the reagent (Roche Diagnostics, Indianapolis, IN).
Endothelial Cell Tube Formation Assay
PAE/VEGFR-2 and PAE/VEGFR-1 cells plates on Matrigel were treated with 0.01 - 100 nM VEGF121/rGel or rGel, in triplicate, for 24 h. Inhibition of tube formation was assessed by counting the number of tubes formed per well under bright field microscopy. The ability of VEGF121/rGel to inhibit tube formation as a function of incubation time before plating on Matrigel was studied by incubating PAE/VEGFR-2 cells at the IC50 dose (1 nM) for different periods up to 24 h. Cells were detached and plated in 96-well Matrigel-coated plates under the conditions described above and the tubes in each well were counted.
Angiogenesis Assessment in Chicken Chorioallantoic Membranes
Chorioallantoic membrane (CAM) experiments using fertilized chicken eggs (SPAFAS; Charles River Laboratories, Wilmington, MA) were performed as described . Experiments were performed twice per treatment, with 6 to 10 embryos per condition in every experiment. Each CAM was locally treated with filter disks saturated with a solution containing bFGF (50 ng/disk) and VEGF121/rGel (1 or 10 nM), rGel (1 or 10 nM), or buffer (PBS). The filter was placed on the CAM in a region with the lowest density of blood vessels and, as a reference, in the vicinity of a large vessel. Angiogenesis was documented photographically 3 days after treatment; images were captured using an Olympus stereomicroscope (SZ x12) and Spot Basic software (Diagnostic Instruments, Inc.). The relative vascular density was determined by measuring the area occupied by blood vessels  using the public domain NIH Image program (available on the Internet at http://rsb.info.nih.gov/nih-image/). The numbers of blood vessel branch points were independently and blindly quantified by two researchers (C.G-M. and J.X.) and compared with the numbers in the treatment controls .
RNA Extraction, Gene Expression Analysis, and RT-PCR Correlative Analysis
HUVECs and PAE/VEGFR-2 cells were treated with their respective IC50 VEGF121/rGel doses for 24 h. Control cells were treated with PBS. Total RNA was extracted and analyzed for integrity as described . HUVEC RNA was amplified and labeled using Cy3- and Cy5-dCTP in the reverse transcription reaction. Duplicate experiments were conducted by dye swapping. The labeled samples were hybridized to a cDNA array of 2304 sequence-verified clones in duplicate printed by the Cancer Genomics Core Laboratory (MDACC). The array included 4800 genes involved in signal transduction, stress response, cell cycle control, hypoxia, and metastatic spread. Differentially expressed genes were identified on the basis of a cutoff value of the T value. Generally, a cutoff value of |3| is considered statistically significant. Genes that showed fold changes greater than |2| in at least 3 of 4 arrays were identified, and the average fold change was determined. Microarray data were verified by performing RT-PCR analysis on the genes that showed the highest level of induction, namely E-selectin (SELE), cytokine A2 (SCYA2, MCP-1), tumor necrosis factor alpha induced protein 3 (TNFAIP3) and NF-κB inhibitor alpha (NF-κBIα). Primers were designed on the basis of the accession numbers from the microarray and confirmation of homology using BLAST (NCBI). Induction of E-selectin in PAE/VEGFR-2 cells was also verified by RT-PCR. GAPDH primers were used as controls.
VEGF121/rGel binds to both VEGFR-1 and VEGFR-2
VEGF121/rGel is internalized into PAE/VEGFR-2 cells but not into PAE/VEGFR-1 cells
Because VEGF121/rGel appears to bind VEGFR-1, we examined the role of internalization to explain the lack of cytotoxicity of VEGF121/rGel on PAE/VEGFR-1 cells. After incubation of cells with VEGF121/rGel, the cell surface was stripped to probe only for internalized protein. VEGF121/rGel was detected in PAE/VEGFR-2 cells within 1 hour of treatment with the immunofluorescence signal progressively increasing by 24 hours (Figure 1C). No VEGF121/rGel was detected in PAE/VEGFR-1 cells up to 24 hours after treatment with the fusion toxin. Because no internalization is observed into PAE/VEGFR-1 cells at both short and long time points, it is unlikely that differences in receptor recycling rates, if any, in the two receptor-transfected cells contribute to these observations. Treatment of cells with the same concentration of gelonin also showed no internalization (see Additional file 1), confirming that entry of VEGF121/rGel into PAE cells occurred almost exclusively via VEGFR-2.
VEGF121/rGel cytotoxicity on endothelial cells correlates with exposure time
Because VEGF121/rGel internalized into PAE/VEGFR-2 cells within one hour of incubation, we studied the cytotoxic effect of VEGF121/rGel as a function of exposure time of this agent on endothelial cells. PAE/VEGFR-2 cells were treated with VEGF121/rGel from 1-72 hours and the cytotoxic effect was assessed at the end of the 72-hour period. VEGF121/rGel demonstrated targeted toxicity even after a one-hour exposure, with an IC50 of 5 nM. The maximal cytotoxic effect of VEGF121/rGel on PAE/VEGFR-2 cells was observed at 48 and 72 hours (IC50 = 0.1 nM) (Figure 1D). The cytotoxic effect of VEGF121/rGel on PAE/VEGFR-1 cells was similarly affected as a function of exposure duration (see Additional file 2) in that longer exposure times resulted in higher cytoxicity with the maximum cytotoxic effect occurring at 72 h (IC50 = 100 nM).
VEGF121/rGel treatment activates VEGFR-2 downstream signaling
Cytotoxic effects of VEGF121/rGel on endothelial cells are not mediated via apoptotic mechanisms
Nuclei of positive control PAE/VEGFR-2 cells showed intense TUNEL staining (Figure 2B). In contrast, no TUNEL staining was observed with PAE/VEGFR-2 cells exposed to VEGF121/rGel up to 72 hours, indicating that the mechanism of cytotoxicity of VEGF121/rGel did not involve apoptosis. To confirm this observation, we examined various key apoptotic signaling events using Western blot analysis. Levels of caspase-3 (full length pre-cursor), Bax (a pro-apoptotic protein), and Bcl-XL (an apoptosis inhibitor) were not found to be affected by VEGF121/rGel treatment (Figure 2C). In addition, the p11 and p20 subunits of activated/cleaved caspase-3 were not detected after treatment with the fusion construct. Levels of the pro-apoptotic molecules cytochrome C and caspase-6, as well as the anti-apoptotic protein Bcl-2 were undetectable before or after treatment (data not shown). PARP cleavage was tested on PAE/VEGFR-2 cells by treating cells with VEGF121/rGel or VEGF121 for periods ranging from 5 minutes to 48 hours. Western blot analysis of these cells by an anti-PARP antibody showed that neither VEGF121/rGel nor VEGF121 activated PARP-mediated apoptosis (Figure 2D; VEGF121 data in Additional file 3).
VEGF121/rGel inhibits tube formation in VEGFR-2-expressing endothelial cells
VEGF121/rGel inhibits angiogenesis in the CAM of chicken embryos
Microarray analysis of HUVECs treated indicates VEGF121/rGel upregulates genes involved in inflammation, chemotaxis and transcription regulation
HUVEC genes that increase following treatment with VEGF121/rGel for 24 hours, compared to untreated cells
E-selectin (endothelial adhesion molecule 1) a
Vascular cell adhesion molecule 1
Plasminogen activator, urokinase
Tumor necrosis factor alpha-induced protein 3 a
baculoviral IAP repeat-containing 3
jun B proto-oncogene
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha a
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
Kruppel-like factor 4
small inducible cytokine A2 (MCP-1) a
small inducible cytokine A4 (MIP-1β)
small inducible cytokine A7 (MCP-3)
chemokine (C-X-C motif), receptor 4 (fusin)
kinesin-like 5 (mitotic kinesin-like protein 1)
H2A histone family, member L
small inducible cytokine A11 (Cys-Cys)
(eotaxin) early growth response 1
prostaglandin-endoperoxide synthase 2 (COX-2)
syndecan 4 (amphiglycan, ryudocan)
dual specificity phosphatase 5 (MKP-1)
Surprisingly, we did not observe E-selectin protein expression in HUVECs in control and 24 h - treated cells (data not shown). However, induction of E-selectin mRNA was observed (see Additional file 4) suggesting that the ribosomal machinery had been effectively inhibited. Because PAE/VEGFR-2 cells have been used as in vitro models for endothelial cells in the tumor neovasculature, we investigated the effect of VEGF121/rGel on gene induction and protein expression in these cells. PAE/VEGFR-2 cells were treated with saline or the IC50 dose of VEGF121/rGel for up to 48 h. PCR analysis for E-selectin confirmed the increase in message within 2 h after treatment of cells with VEGF121/rGel (Figure 5B). In addition, Western blot analysis demonstrated a slight increase in E-selectin protein expression, although the increase in cellular protein levels was modest compared with the observed increase in message, and was obvious only up to 4 h after treatment (Figure 5C). MKP-1 RNA levels were upregulated 2.7-fold in HUVECs (Table 1). Western blots against MKP-1 and ERK2, previously shown to be upregulated by MKP-1 in HUVECs following injury, also showed no change in protein expression (see Additional file 5).
Tumor neovascularization is highly dependent upon numerous cytokines and signaling events critical for the growth and organization of the vascular tree. A number of agents targeting tumor neovascularization and which interfere with one or several steps in this robust process have demonstrated significant clinical efficacy and have received FDA approval . These include agents which block angiogenesis signaling events by inhibiting various growth factor receptor kinases ; interfere with VEGF physical interaction with its receptors such as anti-VEGF antibodies (bevacizumab and ranibizumab) and anti-receptor antibodies (IMC-1121B and DC101) [26, 27]; and strategies that trap growth factor ligands (VEGF-Trap) . These have all shown antitumor efficacy alone and in combination with conventional antitumor modalities [29, 30].
VEGF-A has been shown to play an important role in tube formation of endothelial cells in vitro  and in angiogenesis . In the present study, the effect of VEGF121/rGel on tube formation of endothelial cells on Matrigel-coated plates was striking in that cells overexpressing VEGFR-2, but not cells overexpressing VEGFR-1, were affected. This result is consistent with our findings that VEGF121/rGel is cytotoxic only to VEGFR-2-expressing endothelial cells  and is internalized only into endothelial cells that express VEGFR-2 but not VEGFR-1 (this study). The inhibition by VEGF121/rGel of tube formation in vitro translates well to inhibition of both vascular endothelial growth and neovasculature in vivo in the CAM membrane assays. The CAM assay also demonstrated that treatment with VEGF121/rGel did not affect mature vessels. This critical finding supports our hypothesis that VEGF121/rGel does not affect mature vessels in either normal tissues or tumors since both VEGFR-1 and VEGFR-2 are over-expressed on the endothelium of tumor neovasculature [33–36] but are almost undetectable in the vascular endothelium of adjacent normal tissues and in mature tumor vessels. Therefore, small, newly vascularizing tumors and metastases may be the lesions most responsive to therapy with this agent.
The lack of internalization of VEGF121/rGel into PAE/VEGFR-1 cells explains the difference in cytotoxicity compared to PAE/VEGFR-2. This also supports the hypothesis that VEGFR-1 is a decoy receptor, at least on endothelial cells, as it demonstrates weak tyrosine phosphorylation upon VEGF stimulation . However, we have demonstrated that mouse monocytes internalize VEGF121/rGel via VEGFR-1 , suggesting that other factors may influence VEGFR-1 receptor activity such as cell type, total receptor number and dimerization partner.
While the mechanism of rGel itself is to target the ribosomal machinery, the extent to which translation is inhibited will affect downstream cellular responses, such as other mechanisms of cell death. Information about these mechanisms may reveal additional pathways that can be targeted in combination with the fusion toxin to achieve optimal efficacy. Our study demonstrates that the cytotoxic effect of VEGF121/rGel on VEGFR-2-overexpressing endothelial cells is not due to programmed cell death (apoptosis). Previous studies of a gelonin-based immunotoxin targeting tumor cells showed that intoxicated cells did not appear to display apoptotic characteristics . In contrast, gelonin coupled to BlyS induced apoptosis in B cells  strongly supporting the idea that cell type differences can affect the mechanism of cytotoxicity.
A critical finding of this study is the identification of several genes that are regulated in response to treatment with the VEGF121/rGel fusion construct. We observed an increase in the RNA levels of several genes that are involved in inflammation, chemotaxis, intermediary metabolism, and apoptotic pathways (Table 1). To our knowledge, this microarray analysis is the first to be performed on cells treated with a gelonin-based therapeutic. A previous report showed that only two of these genes, MKP-1 and CXCR4, were also upregulated in HUVECs after treatment with VEGF165 for 24 h . The present study shows that VEGF121/rGel is a member of the class of molecules that can prevent E-selectin-mediated metastasis because protein levels barely doubled in both PAE/VEGFR-2 and HUVECs after treatment with VEGF121/rGel. We observed a similar pattern of induction of RNA but not protein levels with other genes as well. Several genes involved in the control of the apoptotic pathway were modulated in response to the fusion toxin even though the overall cytotoxic effect on target cells did not include an observable impact on the apoptotic pathway. Taken together, we conclude VEGF121/rGel induces an increase in mRNA levels of genes that are important in cell adhesion, migration, and inflammatory response but generally does not induce a concomitant increase in protein expression. Since the rGel component of the fusion construct operates by inhibiting protein synthesis, VEGF121/rGel could inhibit synthesis of critical proteins that are important for suppression of these specific genes. In our laboratory, current studies are under way in breast and prostate orthotopic and metastatic (i.e., lung and bone) tumor models to further characterize the effects of this drug in vitro and in vivo.
Our study shows that the specific cytotoxic effect of VEGF121/rGel observed against tumor vasculature in vivo is due to targeting of endothelial cells that overexpress VEGFR-2. VEGF121/rGel is rapidly internalized into log-phase endothelial cells via VEGFR-2 and mediates a robust cytotoxic effect that is primarily necrotic and negates the upregulation of genes involved in inflammation, chemotaxis and transcription regulation. However, modulation of these genes may influence tumor development in addition to exerting direct cytotoxic effects on the tumor neovasculature. Therefore, important considerations for future study are the effects of VEGF121/rGel cytotoxicity on tumor endothelial cells and the potential bystander effects of the construct on adjacent cells in the tumor microenvironment.
Research conducted, in part, by the Clayton Foundation for Research. Research supported by DAMD 17-02-1-0457 and NIH/NCI P30 CA16672. Work done at the Cancer Genomics Core Lab was supported by the Tobacco Settlement Funds appropriated by the Texas State Legislature, by a generous donation from the Michael and Betty Kadoorie Foundation, by a grant from the Goodwin Fund, and by Cancer Center Core Grant P30 CA016672 28 from the National Cancer Institute.
- Siemann DW, Horsman MR: Vascular targeted therapies in oncology. Cell Tissue Res. 2009, 335: 241-248. 10.1007/s00441-008-0646-0.View ArticlePubMedGoogle Scholar
- Bernatchez PN, Rollin S, Soker S, Sirois MG: Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem. 2002, 85: 629-639. 10.1002/jcb.10155.View ArticlePubMedGoogle Scholar
- Han YS, Lee JE, Jung JW, Lee JS: Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009, 247: 541-548. 10.1007/s00417-008-0976-3.View ArticlePubMedGoogle Scholar
- Karamysheva AF: Mechanisms of angiogenesis. Biochemistry (Mosc). 2008, 73: 751-762. 10.1134/S0006297908070031.View ArticleGoogle Scholar
- Pourgholami MH, Morris DL: Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem. 2008, 6: 343-347. 10.2174/187152508785909528.View ArticlePubMedGoogle Scholar
- Zeng H, Dvorak HF, Mukhopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001, 276: 26969-26979. 10.1074/jbc.M103213200.View ArticlePubMedGoogle Scholar
- Crawford Y, Ferrara N: VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009, 335: 261-269. 10.1007/s00441-008-0675-8.View ArticlePubMedGoogle Scholar
- Dvorak HF: VPF/VEGF and the angiogenic response. Semin Perinatol. 2000, 24: 75-78. 10.1016/S0146-0005(00)80061-0.View ArticlePubMedGoogle Scholar
- Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG: The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia. 2005, 7: 912-920. 10.1593/neo.05292.View ArticlePubMedPubMed CentralGoogle Scholar
- Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG: In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA. 2002, 99: 7866-7871. 10.1073/pnas.122157899.View ArticlePubMedPubMed CentralGoogle Scholar
- Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG: The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia. 2005, 7: 486-496. 10.1593/neo.04631.View ArticlePubMedPubMed CentralGoogle Scholar
- Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG: Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 2006, 66: 10919-10928. 10.1158/0008-5472.CAN-06-0459.View ArticlePubMedGoogle Scholar
- Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone N: Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res. 2011Google Scholar
- Akiyama H, Mohamedali KA, RL ES, Kachi S, Shen J, Hatara C, Umeda N, Hackett SF, Aslam S, Krause M, Lai H, Rosenblum MG, Campochiaro PA: Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol Pharmacol. 2005, 68: 1543-1550.PubMedGoogle Scholar
- Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X: Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med. 2007, 48: 445-454.PubMedGoogle Scholar
- Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996, 271: 7788-7795. 10.1074/jbc.271.13.7788.View ArticlePubMedGoogle Scholar
- Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, Gerritsen ME: Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol. 2002, 22: 1797-1803. 10.1161/01.ATV.0000038995.31179.24.View ArticlePubMedGoogle Scholar
- Kroll J, Waltenberger J: A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun. 1999, 265: 636-639. 10.1006/bbrc.1999.1729.View ArticlePubMedGoogle Scholar
- Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994, 269: 26988-26995.PubMedGoogle Scholar
- Kanellopoulos J, Rossi G, Metzger H: Preparative isolation of the cell receptor for immunoglobulin E. J Biol Chem. 1979, 254: 7691-7697.PubMedGoogle Scholar
- Ran S, Huang X, Downes A, Thorpe PE: Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia. 2003, 5: 297-307.View ArticlePubMedPubMed CentralGoogle Scholar
- Brooks PC, Montgomery AM, Cheresh DA: Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol. 1999, 129: 257-269.PubMedGoogle Scholar
- Jiang BH, Zheng JZ, Aoki M, Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA. 2000, 97: 1749-1753. 10.1073/pnas.040560897.View ArticlePubMedPubMed CentralGoogle Scholar
- Verhoef C, de Wilt JH, Verheul HM: Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharm Des. 2006, 12: 2623-2630. 10.2174/138161206777698756.View ArticlePubMedGoogle Scholar
- Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003, 111: 1287-1295.View ArticlePubMedPubMed CentralGoogle Scholar
- Veronese ML, O'Dwyer PJ: Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer. 2004, 40: 1292-1301. 10.1016/j.ejca.2004.02.014.View ArticlePubMedGoogle Scholar
- Zondor SD, Medina PJ: Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004, 38: 1258-1264. 10.1345/aph.1D470.View ArticlePubMedGoogle Scholar
- Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002, 99: 11393-11398. 10.1073/pnas.172398299.View ArticlePubMedPubMed CentralGoogle Scholar
- Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008, 26: 399-405. 10.1200/JCO.2007.11.9230.View ArticlePubMedGoogle Scholar
- Ma J, Waxman DJ: Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008, 7: 3670-3684. 10.1158/1535-7163.MCT-08-0715.View ArticlePubMedPubMed CentralGoogle Scholar
- Aoki M, Kanamori M, Yudoh K, Ohmori K, Yasuda T, Kimura T: Effects of vascular endothelial growth factor and E-selectin on angiogenesis in the murine metastatic RCT sarcoma. Tumour Biol. 2001, 22: 239-246. 10.1159/000050622.View ArticlePubMedGoogle Scholar
- Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M: Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther. 2002, 1: 295-302.PubMedGoogle Scholar
- Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, Aharinejad S: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg. 2002, 37: 582-587. 10.1053/jpsu.2002.31614.View ArticlePubMedGoogle Scholar
- Ferrara N, Gerber HP: The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001, 106: 148-156. 10.1159/000046610.View ArticlePubMedGoogle Scholar
- Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A: Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol. 2002, 33: 863-870. 10.1053/hupa.2002.126879.View ArticlePubMedGoogle Scholar
- Verheul HM, Pinedo HM: The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGF-Receptor Kinase Inhibitors. Clin Breast Cancer. 2000, 1 (Suppl 1): S80-S84.View ArticlePubMedGoogle Scholar
- Rosenblum MG, Cheung LH, Liu Y, Marks JW: Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res. 2003, 63: 3995-4002.PubMedGoogle Scholar
- Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG: The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther. 2007, 6: 460-470. 10.1158/1535-7163.MCT-06-0254.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/358/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.